OxyNov, a company that, over the course of its development, has benefited from SOVAR support for over four years, has announced that it has concluded a major funding round of $1.5M from private Quebec investors, including Desjardins-Innovatech. This financial assistance will allow OxyNov to commercialize the first generation of the FreeO2 in Europe and to continue innovating by developing in Quebec a complete line of instruments, consumables and services for oxygen therapy needs in hospitals, ambulances and patients’ homes.
It is worth recalling that the FreeO2 is a medical device used in oxygen therapy that automatically controls oxygen titration and patient weaning based on their condition or specific oxygenation needs. FreeO2 represents a key international innovation in oxygen therapy and targets, in the initial stage, pneumology, cardiology, neurology, pediatric and emergency departments in private and public hospitals.

More informations in the Press Release.

SOURCE: SOVAR.